Reviewing the latest research on value-based care, clinical pathways, and precision medicine
Cancer care pathways in secondary/tertiary care demonstrate a positive effect on length of stay, according to a recent study.
Study results suggest pay-for-performance programs may be effective in increasing evidence-based oncology drug prescribing but may not yield cost savings.
Study results support the use of NGS to detect and evaluate MRD in patients with MM, which showed comparable efficacy and applicability to NGF.
The FDA granted approval to pralsetinib for patients with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer requiring systemic therapy.
Researchers from Mayo Clinic designed treatment algorithms for newly diagnosed and relapsed MM based on nonrandomized data and expert opinion.
The number of ICU admissions for patients with metastatic breast cancer at the end-of-life have increased over time, according to a study of commercially insured patients in the US.
Immune checkpoint inhibitor therapy deliver in a real-world setting significantly improves survival in patients aged 65 years and older with cutaneous metastatic melanoma.
Researchers developed guideline-based indicators for diagnosis, therapy, and provider/infrastructural characteristics for the care of adult patients with MDS.
Study results show Medicare payment rates for Mohs micrographic surgery more than double those of other procedures for skin cancer.
The Radiation Oncology Alternative Payment Model encourages shorter courses of radiotherapy, but emerging technologies with large capital and operating investment needs may see reductions in reimbursements.
NGS panel using ctDNA demonstrates high accuracy identifying the 6 actionable oncogenic driver alterations in patients with advanced NSCLC.
Study results show population-wide genomic screening for hereditary breast and ovarian cancer is cost-effective among younger women but not older women in the US.